6.08
+0.13(+2.18%)
Currency In USD
| Previous Close | 5.95 |
| Open | 6.02 |
| Day High | 6.14 |
| Day Low | 5.96 |
| 52-Week High | 11.8 |
| 52-Week Low | 4.44 |
| Volume | 61,771 |
| Average Volume | 132,452 |
| Market Cap | 154.78M |
| PE | -5.24 |
| EPS | -1.16 |
| Moving Average 50 Days | 6.67 |
| Moving Average 200 Days | 7.5 |
| Change | 0.13 |
If you invested $1000 in Nuvectis Pharma, Inc. (NVCT) since IPO date, it would be worth $1,870.77 as of September 29, 2025 at a share price of $6.08. Whereas If you bought $1000 worth of Nuvectis Pharma, Inc. (NVCT) shares 2 years ago, it would be worth $471.68 as of September 29, 2025 at a share price of $6.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
GlobeNewswire Inc.
Sep 25, 2025 12:00 PM GMT
Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:30 AM GMT
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of seriou
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
GlobeNewswire Inc.
Aug 11, 2025 8:30 PM GMT
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients wit
Data not available